



Republic
of Poland



MEDICAL
RESEARCH
AGENCY

Wrocław, 17.07.2026

Request for tender no. ABM/1/26/ZF

Name of Order:

“Development of a Syngeneic Mouse Model and Execution of In Vivo PK/PD Studies Using CRBN-Humanized Mice”

Project:

“Design and clinical development of the first-in-class small-molecule drug candidate in colorectal cancer therapy, based on the immune cells stimulation to enhanced anti-cancer activity through induced protein degradation.”

Order co-financed by the state budget from the Medical Research Agency



Republic
of Poland



MEDICAL
RESEARCH
AGENCY

SECTION I: ORDERING ENTITY

I.1 Name and address of the ordering entity

Captor Therapeutics S.A.

ul. Duńska 11

54-427 Wrocław

NIP 8943071259

I.2. Mode of proceeding

This procedure is awarded on the basis of market discernment.

The contracting authority is not obliged to conduct the proceedings in accordance with the Public Procurement Act.

I.3. Information about the project

The project co-financed from the state budget from the Medical Research Agency under the Competition no. ABM/2022/6 entitled. "Development of targeted or personalized medicine based on therapy with nucleic acids or small-molecule compounds, KWAS".

Contract No. 2022/ABM/06/00001 - 00.

SECTION II: SUBJECT MATTER OF THE CONTRACT

II.1 Definition of the subject matter of the contract

The subject of the order is Development of a Syngeneic Mouse Model and Execution of In Vivo PK/PD Studies Using CRBN-Humanized Mice, for the purposes of implementing the project :

"Design and clinical development of the first-in-class small-molecule drug candidate in colorectal cancer therapy, based on the immune cells stimulation to enhanced anti-cancer activity through induced protein degradation."

CPV code: 73111000-3 - Research laboratory services



II.2.1. Defining the subject of the order:

Development of a Syngeneic Mouse Model and Execution of In Vivo PK/PD Studies Using CRBN-Humanized Mice, including:

Task 1. Validation of the in vivo research model including:

- a) Culturing cancer cells (MC38 or CT26 cell lines) intended for inoculation into mice of a strain with a humanized CRBN protein. The Contractor is obliged to ensure the purchase of animals of a strain carrying at least two mutations in the CRBN protein, i.e., V380E and I391V, resulting in the humanization of this protein. A model with a fully humanized CRBN is also acceptable. The Contractor is obliged to ensure the purchase of mice from certified vendors
- b) Purchase, transport, and housing of 16 mice of the above-mentioned strain;
- c) Subcutaneous inoculation of all 16 mice with cancer cells (2 groups of 8 mice each: two different cancer cell inoculation densities will be tested);
- d) Measurement of tumor growth and body weight of the animals twice weekly for up to 6 weeks;
- e) Collection of tissues (spleen – one per mouse) from half of the animals at one time point (terminal);
- f) Processing of the collected samples: isolation of splenocytes from the spleens;
- g) Analysis of the isolated splenocytes by Western Blot to determine the levels of 2 different proteins with similar molecular weight, normalized to total protein content using the Stain-Free Blot method;
- h) Preparation and submission of appropriate reports to the Contracting Authority.
- i) Completion period: from the date of contract signing, no later than 30.11.2026.
- j) Positive validation criterion: the basis for recognizing the validation of the in vivo research model within Task 1 as positive is the fulfillment of the following criterion: achieving a tumor size of minimum 100 mm³ within 7–14 days of inoculation for over 60% of the animals.

Task 2. PK/PD and tolerability study in healthy mice including:

- a) Purchase, transport, and housing of 160 mice of a strain with the humanized CRBN protein. The Contractor is obliged to ensure the purchase of animals of a strain carrying at least two mutations in the CRBN protein, i.e., V380E and I391V, resulting in the humanization of this protein. A model with a fully humanized CRBN is also acceptable. The Contractor is obliged to ensure the purchase of mice from certified vendors – the same strain as in Task 1 is required;
- b) Oral administration of the test compounds to the animals (1 group of 10 mice receiving vehicle; and 30 groups of 5 mice each – each group will receive one of the five test compounds at one of the three tested dose levels) – half of the mice will receive a compound as a single dose, while the other half will receive multiple doses (once daily for 3 days);
- c) Collection of blood (one sample per mouse, terminal) and tissues (spleen – one per mouse, terminal) from all animals at one of two selected time points (6 hours after the first dose or 24 hours after the third dose; one time point per group);



- d) Processing of the collected samples: plasma isolation from blood and splenocyte isolation from the spleens;
- e) Analysis of the isolated splenocytes (from 160 mice) by Western Blot to determine the levels of 2 different proteins with similar molecular weight, normalized to total protein content using the Stain-Free Blot method;
- f) Development of an LC-MS/MS method for measuring the concentration of a small-molecule (test compound) in plasma and performance of these measurements for 150 plasma samples;
- g) Preparation and submission of appropriate reports to the Contracting Authority.
- h) Completion period: from 01.11.2026, no later than 30.04.2027.

The subject of the procurement constitutes one comprehensive contract covering the validation of the research model (Task 1) and the performance of PK/PD studies and biological analyses (Task 2). The tasks are closely interconnected from a scientific, methodological, and organizational perspective. The results obtained within Task 1 constitute the basis for the implementation of Task 2 and require consistency of the research model, experimental procedures, analytical methods, and interpretation of results. Therefore, the subject of the procurement constitutes one indivisible whole, and the Contracting Authority does not allow the submission of partial bids.

Contract performance:

During the performance of the contract, the Contractor shall prepare and submit to the Contracting Authority technical reports (in electronic and/or paper form, using recycled paper) describing the results of the implementation of individual experiments/tasks in the form of Excel files containing raw experimental data, as well as processed versions including statistical analysis. The Contractor shall submit the technical reports upon completion of each experiment/task resulting from the contract or once a week (depending on the arrangements between the parties). If there is no justification for preparing a technical report, the progress of the work shall be reported electronically in the form of a brief note. The details regarding reporting shall be specified in the Agreement.

II.2.2. Subject Implementation Conditions

- 1. Task 1 implementation period: From the date of signing the Agreement, but **no later than 30 November 2026**.
- 2. Task 2 implementation period: From 1 November 2026, but **no later than 30 April 2027**.
- 3. Task 2 may commence in parallel with the final stage of Task 1, following confirmation of successful model validation (In accordance with the criterion contained in point II.2.1, point j)) or upon obtaining results that enable the initiation of the PK/PD studies.
- 4. If the model validation is unsuccessful (In accordance with the criterion contained in point II.2.1, point j)) or if the results obtained under Task 1 do not support the studies envisaged under Task 2, the Client reserves the right to withdraw from the implementation of Task 2. In such a case, the Contractor shall have no claim for the performance of Task 2 or for any remuneration in respect of its non-performance.



5. The Ordering Party allows the possibility of delay in the order execution as a result the force majeure¹, whose consequences could not have been avoided. In a justified situation where the timely (due to the "Order form" or Agreement) execution of the order is not possible, Contractor shall inform the Ordering party about any delays.

Note: The cost of the service includes all costs related to the execution of the subject matter of the contract, including but not limited to reagents, equipment, salaries.

II.3 Conditions

1. Partial bids are not allowed.
2. Variant bids are not allowed.
3. The binding period with the bid: minimum 60 days from the deadline for submission of tenders, with the first day of the tender period being the day on which the deadline for submission of tenders expires.
4. The Ordering Party reserves the right to cancel the request for tender without giving reasons, and may do so at any time without liability to Bidders who submitted bids.

II.4 Requirements for Bidders:

The Contracting Authority stipulates that taking part in the tender process can only Bidder who:

- a) Have experience in providing research services, including no fewer than 10 projects over the last 5 years concerning potency (efficacy) studies of therapeutic agents (e.g. ICI antibodies, bifunctional antibodies, small-molecule compounds) in syngeneic and/or immuno-oncology (humanized) animal models, for partners from the pharmaceutical industry.
- b) Have personnel with experience and expertise in performing analyses of animal tissues using the Western Blot method, as well as analyses of the concentrations of chemical compounds in body fluids or animal tissues.
- c) Have access to mice of a strain with humanized CRBN (minimum two mutations in the CRBN protein, i.e., V380E and I391V, which cause humanization of this protein (therefore, a model with fully humanized CRBN is acceptable)) – it is required to provide data including confirmation of the absence or strong reduction of mouse (WT) CRBN expression, with simultaneous strong (dominant) expression of humanized CRBN, at least in: the spleen, colon, and heart.
- d) Have a validated syngeneic model using MC38 or CT26 cells – it is required to provide data including tumor growth curves with accompanying measurement of mouse body weight, as

¹ „force majeure” is understood by both sides to mean as an event beyond the control of (i) the Parties which (ii) prevents proper execution of one or more contractual obligations in spite of proper adherence to the due diligence RFP, (iii) The event (iv) is external and irresistible, unforeseeable with due diligence; whose consequences are irreversible and could not have been avoided. When described conditions can be considered to be fulfilled, the „Force majeure” involved include in particular:

a) exceptional disturbances in collective life (including: wars (also on the territory of others country when its causes has impact on Poland (i.e. sanctions); state of emergency; military operations; invasions; mobilizations; requisitions; terrorism), pandemics, epidemics.

b) the occurrence of radioactive radiation and radiation contamination

c) natural disasters such as earthquakes, floods or other events considered as a disaster in accordance with applicable regulations of affected country.



well as the response of the model to standard chemotherapy (Standard of Care, SoC) and/or an antibody of the ICI type (Immune Checkpoint Inhibitors).

From the contractor selection procedure are excluded bidders who are personally or financially related to the ordering entity. Financial or personal ties are understood as the relationship between the bidder and the ordering entity or the persons authorized to incur liabilities on behalf of the ordering entity or persons performing on behalf of the ordering party activities related to the preparation and conduction of contractor selection procedure, consisting particularly of:

- a) participating in the company as a partner in a civil law partnership or a partnership, holding at least 10% of shares or stocks (unless a lower threshold is required by applicable law), or serving as a member of a supervisory or management body, a commercial proxy (prokurent), or an attorney-in-fact;
- b) being married to, related by blood or affinity in the direct line, related by blood or affinity in the collateral line up to the second degree, or connected through adoption, guardianship or custodianship, or cohabiting with the contractor, its legal representative, or members of the management or supervisory bodies of contractors participating in the procurement procedure;
- c) having such a legal or factual relationship with the contractor as to give rise to justified doubts regarding their impartiality or independence in connection with the procurement procedure.

Evaluation of the fulfillment of the aforementioned conditions will be made on the basis of fulfillment / non-fulfillment.

Bidders that do not meet the conditions described in Section II.3 and II.4 will be excluded from the proceeding

II.5 Submission of bids:

II.5.1. Basic requirements

1. Each Bidder may submit only one bid.
2. The bid and its appendices must be signed by persons authorized to represent the Bidder. If the authority of the signatory does not result from the document stating the legal status (e.g. KRS), the offer must be accompanied by appropriate authorization.
3. The bid and its attachments should be sent electronically.
4. The contracting authority allows the submission of a bid:
 - in the form of a scan of the offer previously bearing his or her handwritten signature,
 - in document form (as referred to in Article 77³ of the Civil Code - electronic document form), i.e. signed files especially with the qualified electronic signature, trusted



electronic signature, personal electronic signature, DocuSign, deSignatures, digital representation are recognized as the original

5. The Ordering Party recommends that the bid and the attachments to the tender be prepared on the basis of the templates attached to this request for proposals. If the Contractor plans to submit a bid on its own form, it should include in the content of the documents the statements and requirements specified in the model documents attached to the request for proposal.
6. The bid shall be drawn up in Polish or English. Documents or statements drawn up in a foreign language should be submitted with a translation into Polish or English.
7. The cost of preparing and delivering the bid is covered by the Bidder.

II.5.2 Contents of the offer

The bid should include annexes signed by authorized persons:

- a) Annex No. 1 – completed Offer Form together with the declarations concerning the Bidder,
- b) Annex No. 2 – Declaration of the absence of links between the cooperating entities,
- c) Authorization to represent the Bidder – if applicable,
- d) data including confirmation of the absence or strong reduction of mouse (WT) CRBN expression, with simultaneous strong (dominant) expression of humanized CRBN, at least in: the spleen, colon, and heart;
- e) data including tumor growth curves with accompanying measurement of mouse body weight, and the response of the model to standard chemotherapy (Standard of Care, SoC) and/or an antibody of the ICI type (Immune Checkpoint Inhibitors).

II.5.3 Place, term and manner of submitting the bid:

1. Tenders should be submitted electronically to **28.07.2026 by 11:00 a.m.**
2. Please send your offer to: pmo@captortherapeutics.com. In the title of the email, please write: "The bid in the proceeding no. **ABM/1/26/ZF**"
3. Tenders received after the deadline will not be evaluated.

II.6 Evaluation of tenders:

1. The Ordering Party shall carry out formal and substantial evaluation of submitted tenders in accordance with the requirements specified in the Request for Tender and according to the evaluation criteria specified in item II.7.1.
2. **Evaluation by criteria** - in accordance with the evaluation criteria set out in section II.7.1, the Contracting Authority will calculate the number of points for each tender.
3. **Substantive evaluation** - The offer, which obtained the highest number of points (according to II.7.1), is subject to substantive analysis in order to verify the compliance of the offered products with the technical specification presented in Annex No. 1. During the offer analysis, the Ordering Party may ask the Bidder for additional explanations or supplements, if the information contained in the offer does not allow for objective evaluation of the offer. The



Ordering Party shall reject the offer of the Bidder who has not submitted explanations within the set deadline (min. 2 days) or if the evaluation of the explanations confirms that the offer does not comply with the technical specification. In this situation, the Ordering Party shall evaluate the next bid in order according to the score obtained according to item II.7.1. The Ordering Party reserves the right to extend the time for submitting supplements/clarifications.

4. **Formal evaluation** - the Ordering Party shall examine whether the offer which obtained the highest number of points and passed the substantive evaluation satisfies the formal conditions specified in the Request for Tender. The Ordering Party may call upon the Bidder to supplement formal deficiencies of the offer or to submit explanations regarding formal issues. The Ordering Party shall reject the offer of the Bidder who did not submit supplements within the set deadline (min. 2 days) or if the received response confirms that the offer does not meet formal conditions. The Ordering party reserves the right to extend the time for the submission of supplements/clarifications.
5. The bid which obtains the highest number of points and which is in line with the content and meets the formal requirements will be deemed the most advantageous.
6. Following the evaluation of the bids, the Ordering Party will inform the Bidders by e-mail of the selection of the most advantageous bid
7. The Ordering Party rejects a tender if:
 - a) its content does not correspond to the content of this request for proposals or is incomplete,
 - b) its submission constitutes an act of unfair competition within the meaning of the rules on unfair competition,
 - c) The bidder did not submit clarifications/additions to the Ordering Party request regarding the content of the submitted bid,
 - d) was submitted by a Bidder who does not meet the criteria for this procedure or by a Bidder who is excluded,
 - e) is invalid under separate provisions.
8. from the contractor selection procedure are excluded Bidders who:
 - a) were directly involved in the preparation of the procedure or used persons involved in the preparation of the tender, unless the participation of those economic operators in the procedure does not hinder fair competition,
 - b) have submitted false information affecting or likely to affect the outcome of the proceedings,
 - c) have failed to demonstrate that they meet the conditions for participation in the procedure,
 - d) have a personal or capital relationship with the Ordering Party.

The bid of an excluded Bidder shall be considered as rejected.

II.7. Criteria for bids evaluation The Contracting Authority will evaluate the submitted tenders according to the following criteria:



1. Criterion - Price - weight 100 points.

The number of points for the price criterion will be calculated according to the following formula (counting to two decimal places), maximum score: 100 pts.

$$\text{Number of points.} = \frac{\text{minimum bid price PLN net}}{\text{price of the tested offer PLN net}} \times 100 \text{ pts.}$$

2. The evaluation will be based on the net bid price in the Polish zloty (PLN). In the case of bids submitted in a currency other than the Polish zloty, the average exchange rate of the National Bank of Poland as of the last day for the submission of bids with an accuracy of 4 decimal places will be used for currency conversion.
3. The most advantageous bid will be the one that meets the conditions specified in in points. II.2., II.3, II.4,II.5, II.6 , which will obtain the highest number of points.

SECTION III: ADDITIONAL INFORMATION

III.1 Forms of communication

1. All correspondence related to the preparation of tenders, including formal and substantive questions, should be sent at e-mail address: pmo@captortherapeutics.com
2. The Ordering Party will answer questions up to 3 working days from receipt of the enquiry if questions are received no later than 2 working days before the date of submission of tenders (the period of 3 days does not include the day of submission of tenders). When calculating the deadline from the date of the question, please note that the day on which the question is received is not included - the first day of the deadline is the next working day after receipt of the question. The deadline ends on the last working day. Answers will be provided by the Ordering Party by e-mail.
3. The Ordering Party reserves the right to extend the response time and the possibility of extending the deadline if the answers to the questions or issues raised involve a change to the terms of the Order.

III.2 Term of contract execution

Contract period: from the date of signing the Contract until 30 April 2027.

The Ordering Party is planning to sign the Agreement in July 2026.



III.3 Important to both parties provisions of the agreement

1. Once the results of the enquiry have been finalized and made public, the Ordering Party and the Bidder will sign the relevant contract. The selected Bidder shall be obliged to sign the contract within the deadline set by the Ordering Party. If the Bidder, whose bid was selected as the most advantageous, refuses to sign the contract, the Ordering Party may select the next most advantageous bid from among the remaining bids.
2. Due to the nature of the subject matter of the contract, the Ordering Party allows for the possibility of advance and partial payments, during and prior to the execution of the service, the details of which will be agreed with the Contractor during contract negotiations.
3. The contracting authority stipulates that the contract will specify contractual penalties for non-performance or improper performance of the subject matter of the contract.
4. The Ordering Party reserves the right to amend the contract concluded with the Tenderer selected in the course of the procedure in the event of the occurrence of one or more of the circumstances listed below, subject to the conditions specified for their introduction:

4.1 The completion date of the contract may change in the following situations:

- a) the occurrence of force majeure, preventing the timely performance of the subject of the Contract, whereby the Bidder shall be obliged to inform the Ordering Party and specify the force majeure causing the impossibility of timely performance of the contract and indicate the impact that this event has had on the course of performance of the contract
- b) the occurrence of extraordinary circumstances, other than force majeure, preventing the timely performance of the subject of the Agreement, which the Parties, exercising due diligence, did not foresee at the conclusion of the Agreement and are not at fault of the Parties;
- c) suspension of the execution of the contract by the Ordering Party due to the occurrence of technical or organizational reasons which make it impossible to continue the execution of the subject matter of the Contract, by the time of suspension. Ordering Party shall notify the Bidder of the suspension of the contract execution, indicating the reason for the suspension;
- d) the occurrence of changes in the project timetable.

The aforementioned changes may not constitute grounds for an increase in remuneration. Any of the above changes may be associated with a reduction in remuneration.

4.2 The Ordering Party shall allow for the possibility of introducing changes to the subject matter of the Agreement or for the Ordering Party to abandon the execution of a part of the subject matter of the Contract in the event of:

- a) Where, for reasons of extreme urgency and after analysing the test results the Ordering Party decided to change the method/parameters (for example number of compounds;), All changes mentioned in the preceding sentence may constitute grounds for increasing the remuneration. Explanation with proper calculations which directly indicate the amount, term and scope of change must be provided.



- b) the occurrence of force majeure, preventing the execution of the subject of the Contract, whereby the Bidder shall be obliged to inform the Ordering Party and specify the force majeure causing the inability to execute the contract on time, as well as indicate the impact that this event has had on the course of the contract execution
- c) the occurrence of circumstances, other than force majeure, preventing the execution of the subject of the Agreement, which the Parties, exercising due diligence, did not foresee at the conclusion of the Agreement and are not at fault of the Parties, e.g. the occurrence of changes in the Ordering Party's research process, occurrence of changes in the project assumptions,
- d) a change in the applicable legislation affecting the subject matter and terms of the contract and a change in the legal or factual situation of the Bidder and/or the Ordering Party resulting in an inability to perform the subject matter of the contract

The aforementioned changes may not constitute grounds for an increase in remuneration. Any of the aforementioned changes may be associated with a reduction in remuneration.

4.3 The Ordering Party shall allow technical and technological changes in the execution of the subject matter of the Contract, with its prior consent, in the event that:

- a) the unavailability on the market of the materials or equipment indicated in the offer due to the cessation of production or withdrawal from the market of those materials or equipment;
- b) the appearance on the market of newer-generation materials or equipment enabling savings in the costs of implementing the subject of the Order;
- c) the need to perform the subject of the Agreement using other technical or material solutions due to changes in applicable law.

The aforementioned changes may not constitute grounds for an increase in remuneration. Any of the above changes may be associated with a reduction in remuneration.

4.4 If in the course of execution of the project carried out by the Ordering Party, the relevant Institution makes any recommendations concerning any changes to the Project affecting the scope of the Agreement, the Agreement may be amended to the extent corresponding to the changes in the Project

4.5 Form of amendment:

- a) Initiation of changes - at the written request of the Ordering Party and/or the Bidder (letter of information).
- b) Addendum to the contract with the Bidder in writing under pain of nullity.



Republic
of Poland



MEDICAL
RESEARCH
AGENCY

Appendices:

Appendix no. 1 - Bid form

Appendix no. 2 - Statement on the lack of relation between cooperating entities



Appendix no. 2

.....
(place and date)

.....
(name and address of the tenderer)

Statement on the lack of relation between cooperating entities

I declare that the Bidder submitting the bid is not related personally or financially with the ordering party. Financial or personal ties are understood as the relationship between the bidder and the ordering party or the persons authorized to incur liabilities on behalf of the ordering party or persons performing on behalf of the ordering party activities related to the preparation and conduction of contractor selection procedure, in the procedure: ABM/1/26/ZF entitled: **“Development of a Syngeneic Mouse Model and Execution of In Vivo PK/PD Studies Using CRBN-Humanized Mice”** consisting in particular of:

- a) a)participating in the company as a partner in a civil law partnership or a partnership, holding at least 10% of shares or stocks (unless a lower threshold is required by applicable law), or serving as a member of a supervisory or management body, a commercial proxy (prokurent), or an attorney-in-fact;
- b) being married to, related by blood or affinity in the direct line, related by blood or affinity in the collateral line up to the second degree, or connected through adoption, guardianship or custodianship, or cohabiting with the contractor, its legal representative, or members of the management or supervisory bodies of contractors participating in the procurement procedure;
- c) having such a legal or factual relationship with the contractor as to give rise to justified doubts regarding their impartiality or independence in connection with the procurement procedure.

In addition, I declare that the Bidder is not a related party to the Ordering Party, within the meaning of Commission Regulation (EC) No. 1126/2008 of November 3, 2008 adopting certain international accounting standards in accordance with Regulation (EC) No. 1606/2002 of the European Parliament and of the Council.

There are no mentioned above relations between ordering entity and the bidder.

(Stamp, date and signature of the bidder)